2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 550

Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study
Abstract Number: 342

Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout
Abstract Number: 1112

Rheumatologists’ Opinions and Use of Telemedicine in the Southwestern U.S
Abstract Number: 1797

Rheumatology Mechanism Madness: A Pilot Collaborative Learning Activity for Rheumatology Trainees
Abstract Number: 2905

Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial
Abstract Number: 734

Risk Assessment in Connective Tissue Disease Associated Pulmonary Arterial Hypertension
Abstract Number: 202

Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies
Abstract Number: 1607

Risk Factors for Avascular Necrosis in SLE: A Multivariate Model
Abstract Number: 351

Risk Factors for Cutaneous Reactions to Allopurinol in Kinh Vietnameses: Results of a Prospective Study in Ho Chi Minh City
Abstract Number: 2114

Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases
Abstract Number: 1306

Risk Factors for Pain After Total Joint Replacement in Osteoarthritis: Different Pain Measures, Distinct Predictors?
Abstract Number: 2170

Risk Factors for Poor Outcomes After Hip Fracture Patients in the Robust Elderly: Are Patient Reported Outcomes Important?
Abstract Number: 2108

Risk Factors for Pulmonary Nontuberculous Mycobacterial Disease in Rheumatoid Arthritis Patients
Abstract Number: 2300

Risk Factors for Transfusion and Use of Tranexemic Acid in Patients with Rheumatoid Arthritis Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty
Abstract Number: 1840

Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone versus Prednisone Alone

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].